Press releases

202420232022202120202019201820172016201520142013
Press release 2024/04/15
Medivir’s partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release 2024/04/09
Medivir to present at Investing in Oncology Forum on April 10

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2024/04/04 Regulatory
Notice of Annual General Meeting of Medivir AB (publ)

The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the...

Read more
Press release 2024/04/04 Regulatory
Medivir 2023 Annual Report published

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2023 now is available at the...

Read more
Press release 2024/03/06
Medivir to present at Swiss Nordic Bio in Zürich on March 7

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2024/03/04
Medivir to present at the Life Science Day in Gothenburg on March 6

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release 2024/02/26
Change in Medivir's nomination committee before the 2024 AGM

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that that the nomination committee before the annual general meeting in...

Read more
Press release 2024/02/22
Medivir presents data that strengthens the fostrox/Lenvima combination in primary liver cancer at EASL Liver Cancer Summit

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

Read more
Press release 2024/02/15 Regulatory
MEDIVIR AB – YEAR-END REPORT JANUARY – DECEMBER 2023

“The clinical efficacy of fostrox in combination with Lenvima continues to improve with median time to progression having increased to over...

Read more
Press release 2024/01/31 Regulatory
Number of shares and votes in Medivir AB on 31 January 2024

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed...

Read more
Press release 2024/01/26 Regulatory
Medivir announces the outcome of the directed share issue which was announced on 22 January 2024

7,547,170 shares were issued, and all shares have been subscribed for by and allotted to Hallberg Management AB in accordance with...

Read more
Press release 2024/01/24
Medivir to present at the Redeye Fight Cancer Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more